SlideShare a Scribd company logo
ACUTE ORAL TOXICITY- UP
DOWN PROCEDURE (425
GUIDELINE)
NAME-DIXHU RAJ DIXIT
CLASS-M.PHARM PHARMACOLOGY 2ND SEM
ROLLNO-007
INTRODUCTION
• OECD guideline for the testing of chemicals are periodically reviewed in the light of scientific progress or
changing.
• The concept of the up-down testing approach was first described by Dixon and Mood.
• In 1985 Bruce proposed to use an up and down procedure for the determination of acute toxicity of
chemicals
• The study comparing result obtained with the UDP the conventional LD50 test and fixed dose procedure
was published in 1995.
• The test procedure described in the guideline is of value in minimizing the numbering of animals
required to estimate the acute oral toxicity of chemicals
• Guidance on the selection of the most appropriate test method for a given purpose can be found in the
in the guidance document on oral toxicity testing.
INITIAL CONSIDERATION
• The testing laboratory should be consider all available information on the test substance prior to
conducting the study.
• Identity and chemical structure of the test substance its physical chemical properties the result of any
other in vitro and in vivo toxicity test on the substance .
• Toxicological data on structurally related substances or similar mixtures and the anticipated use of the
substance.
• The method permits estimation of an LD50 with a confidence interval and results allow a substance to
be ranked and classified according to globally harmonised system for the classification of chemicals
which cause acute toxicity.
• Dose starting near 175 mg/kg and using half log unit (dose progression by factor 3.2) between doses
will procedure best results.
• Test substance, at doses that are known to cause marked pain and distress due to corrosive or severely
irritant actions, need not be administered.
• The method would not be practical to use when considerly delayed death ( five days Or more) can be
expected.
PRINCIPLE OF LIMIT TEST
• The limit is a sequential test that is uses a maximum of 5 animals. A test dose of 2000, or
expectationally 5000mg/kg , may be used.
• The selection of sequential test plan increases the statistical power and also has been made to
intentionally bias the procedure towards rejection of the limit test for compound with LD50 near the
limit dose.
PRINCIPLE OF MAIN TEST
• The main test consist of a single ordered dose progression in which animals are dosed, on at a time, at
a minimum of 48 hour interval.
• The first animal Receives a dose a step below the level of the best estimate of the LD50.
• If the animal Survive the dose for the next animal is incresed by factor 3.2 times the original dose; if it
dies, the dose for the next animal is decreased by a similar dose progression.
• Each animal should be observed carefully for up to 48 hours before making a decision on whether and
how much to dose the next animal.
• The decission is based on the 48 hour survival pattern of all animals up to that time.
• The LD50 is calculated using the method of maximum likelihood.
DESCRIPTION OF THE METHOD
• SELECTION OF ANIMAL SPECIES—
The preferred rodent species is the rat, normally female rat are used.
• When toxicological and toxicokinetic properties of structurally related chemicals are studied, male are likely to be more sensitive.
• Criteria for femals rats----
• They should be nulliparous and non pregnant.
• Should be between 8 to 12 years old.
• Weight +-20% of initial mean weight.
HOUSING AND FREEDING CONDITIONS-
1.Temperature in the experimental animal room should be 22°c .
2.Humidity should be 30-60% not exceeding 70%.
3.Lightening should be artificial, the sequence being 12 hours light and 12 hours dark.
4.The animal House are individually.
5.For feeding, conventional rodent laboratory diets may be used with in unlimited supply of drinking water.
• PREPARATION OF ANIMAL-
• The animal are randomly selected, marked to permit individual identification, and kept in. Their cages
for at least 5 days prior to dosing to allow for acclimatization to laboratory conditions.
• Ensure that animals are available in the appropriate size and age range for the entire study.
• PREPARATION OF DOSES-
• Test Substances should be administerd in a consent volume by varying the concentration of the dosing
preparation.
• In rodents, the volume should not normally exceed 1ml/100 g of body weight ; however in the case of
aqueous solutions, 2ml/100 g body weight can be considered.
• For vehicle other than water, the toxicological charecterstics of the vehicle should be known.
PROCEDURE
• ADMINISTRATION OF DOSES-
• The test substance is administered in a single dose by gavage using a stomach tube or suitable
intubation cannula.
• Animals should be fasted prior to dosing( ex-rat, food but not water should be witheld overnight ; with
the mouse, food but not water should be witheld for 3-4 hours)
• Animal should be weighed and the test substance administered and the dose is calculated according to
the body weight.
• After the substance has been administered, food may be witheld for a further 3-4 hours in rats or 1-2
hours in mice.
LIMIT TEST AND MAIN TEST
• The limit test is primarily used in Situation where the experimenter has information indicating that the
test material is likely to be nontoxic, I.e.having toxicity below regulatory limit doses.
• There is little or no information about it’s toxicity, or in which the test material is expected to be toxic,
the main test should be performed.
• Information about the toxicity of the test material can be gained from knowledge about similar tested
compounds or similar tested mixtures or products, taking into consideration the identity and
percentage of components.
LIMIT TEST
• Dose one animal at the test dose.
• If the animal dies, conduct the main test to determine the LD50.
• If the animal survives, does four additional animals sequentially so that a total of five animals are tested. If three animals die, the
limit test is terminated and the main test is performed.
• If an animal unexpectedly dies late in the study, and there are other survivors it is appreciate to stop dosing and observe all animals
to see if other animals will also die during a similar observation period.
• The result are evaluated as follows (O= survival, X-Death)
• The LD50 is less than the test dose(2000mg/kg) when three or more animal die.
• O XO XX
• O OX XX
• O XX OX
• O XX X
• If a third animal dies, conduct the main test.
LIMIT TEST AT 5000 MG/KG
• Dose one animal at the test dose.
• If the animal dies, conduct the main test to determine LD50.
• If the Animal survives, dose two additional animals. If both animals survive, the LD50 is greater than the
limit dose and the test is terminated.
• The LD 50 Is less than the test dose( 5000mg/kg) when three or more animal die.
• The LD 50 is greater than the test done (5000mg/kg) when three or more animals survive.
MAIN TEST
• Single animal are dosed in sequence usually at 48 hour intervals
• For selecting starting dose, information on structurally related substances and results of any other
toxicity tests on the test material, should be used to approximate the LD50 as well as the slope of these
dose response curve.
• The dose procession factor should remain constant throughout testing
• When there is no Information on the slope of the substance to be tested, a dose progression factor of
3.2 is used.
• Using default progression factor, doses would be selected from the sequence
1.75,5.5,17.5,55,175,550,2000.
• The testing criteria stops when one of the following stoping criteria first is met------
• 3 consecutive animals survive at thr upper bound
• 5 reversals occur in any 6 consecutive animal tested.
• At least 4 animals have followed the first reversal and the specified likelihood –ratios exceed .
If an animal unexpectedly dies late in the study and there are other survivors at that dose or above, it is
appropriate to stop dosing and observe all animals to see if other animals will also die during a similar
observation period.
If subsequent survivors also die, and it appears that all dose levels exceed the LD50 it would be most appropriate
to start the study again beginning at least two steps below the lowest dose with deaths (and increasing the
observation period) since the technique is most accurate when the starting dose is below the LD50.
If subsequent animals survive at or above the dose of the animal that dies, it is not necessary to change the
dose progression
OBSERVATION
• Animals are observed individually at least once during the first 30 minutes after dosing, periodically
during the first 24 hours (with special attention given during the first 4 hours), and daily thereafter, for a
total of 14 days, except where they need to be removed from the study and humanely killed for animal
welfare reasons or are found dead.
• Observations should include changes in skin and fur, eyes and mucous membranes, and also respiratory,
circulatory, autonomic and central nervous systems, and somatomotor activity and behaviour pattern.
Attention should be directed to observations of tremors, convulsions, salivation, diarrhoea, lethargy,
sleep and coma.
BODY WEIGHT AND PATHOLOGY
Body weight-
Individual weights of animals should be determined shortly before the test substance is administered and
at least weekly thereafter. Weight changes should be calculated and recorded. At the end of the test
surviving animals are weighed and then humanely killed.
Pathology-
All animals (including those which die during the test or are removed from the study for animal welfare
reasons) should be subjected to gross necropsy. All gross pathological changes should be recorded for
each animal.
DATA AND REPORTING
Individual animal data should be provided. Additionally, all data should be summarised in tabular form,
showing for each test dose the number of animals used, the number of animals displaying signs of toxicity
(the number of animals found dead during the test or killed for humane reasons, time of death of
individual animals, a description and the time course of toxic effects and reversibility, and necropsy finding
TEST REPORT AND RESULT
• he test report must include the following information:
•
• Test substance:
• − physical nature, purity and, where relevant, physical-chemical properties (including isomerisation);
• − identification data, including CAS number.
•
• Vehicle (if appropriate):
•
• − justification for choice of vehicle, if other than water.
•

More Related Content

What's hot

skin sensitisation test
 skin sensitisation test skin sensitisation test
skin sensitisation test
mominasran
 
Oral toxicity
Oral toxicityOral toxicity
Oral toxicity
Diana Lou
 
OECD Guidline on acute and chronic toxicity
OECD Guidline on acute and chronic toxicityOECD Guidline on acute and chronic toxicity
OECD Guidline on acute and chronic toxicity
Shital Magar
 
Preclinical screening of anti ulcer drugs
Preclinical screening of anti ulcer drugsPreclinical screening of anti ulcer drugs
Preclinical screening of anti ulcer drugs
Kanthlal SK
 
Female reproductive toxicity studies acoording to SECHDULE Y AND ICH S5R3
Female reproductive toxicity studies acoording to SECHDULE Y AND ICH S5R3Female reproductive toxicity studies acoording to SECHDULE Y AND ICH S5R3
Female reproductive toxicity studies acoording to SECHDULE Y AND ICH S5R3
SONALPANDE5
 
Schedule Y Regulation For Animal Toxicity Studies
 Schedule  Y Regulation For Animal Toxicity Studies Schedule  Y Regulation For Animal Toxicity Studies
Schedule Y Regulation For Animal Toxicity Studies
Cerin Philip
 
Anesthesia and euthanasia of experimental animal by vivek and naveen
Anesthesia and euthanasia of experimental animal by vivek and naveenAnesthesia and euthanasia of experimental animal by vivek and naveen
Anesthesia and euthanasia of experimental animal by vivek and naveen
AnimatedWorld
 
test item characterization of regulatory of toxicological studies
test item characterization of regulatory of toxicological studies test item characterization of regulatory of toxicological studies
test item characterization of regulatory of toxicological studies
SonaliJain736101
 
SUB ACUTE ORAL TOXICITY
SUB ACUTE ORAL TOXICITYSUB ACUTE ORAL TOXICITY
SUB ACUTE ORAL TOXICITY
Arghya Chowdhury
 
Toxicity Studies : Acute Eye Irritation, Dermal Irritation
Toxicity Studies : Acute Eye Irritation, Dermal IrritationToxicity Studies : Acute Eye Irritation, Dermal Irritation
Toxicity Studies : Acute Eye Irritation, Dermal Irritation
Shubhu20
 
Skin sensitisation (OECD: 406).
Skin sensitisation (OECD: 406).Skin sensitisation (OECD: 406).
Skin sensitisation (OECD: 406).
Dr Ajay Mandal
 
OECD Guideline 420: Acute oral Toxicity - Fixed Dose Procedure
OECD Guideline 420: Acute oral Toxicity - Fixed Dose ProcedureOECD Guideline 420: Acute oral Toxicity - Fixed Dose Procedure
OECD Guideline 420: Acute oral Toxicity - Fixed Dose Procedure
KhushbooThakur15
 
Toxicology & Regulatory Guidelines for Conducting Toxicity Study
Toxicology & Regulatory Guidelines for Conducting Toxicity StudyToxicology & Regulatory Guidelines for Conducting Toxicity Study
Toxicology & Regulatory Guidelines for Conducting Toxicity Study
JanhaviBurade
 
Cpcsea guidelines
Cpcsea guidelines Cpcsea guidelines
Cpcsea guidelines
subodhhipr
 
TOXICOKINETICS EVALUATION IN PRECLINICAL STUDIES.pptx
TOXICOKINETICS EVALUATION IN PRECLINICAL STUDIES.pptxTOXICOKINETICS EVALUATION IN PRECLINICAL STUDIES.pptx
TOXICOKINETICS EVALUATION IN PRECLINICAL STUDIES.pptx
Anmolkanda06
 
Schedule y for toxicity studies
Schedule y  for toxicity studiesSchedule y  for toxicity studies
Schedule y for toxicity studies
KrushangiShah233
 
Screening Methods of Antihypertensive Agents
Screening Methods of Antihypertensive AgentsScreening Methods of Antihypertensive Agents
Screening Methods of Antihypertensive Agents
Dr. Advaitha MV
 
Dermal Irritation and Dermal Toxicity Studies
Dermal Irritation and Dermal Toxicity Studies Dermal Irritation and Dermal Toxicity Studies
Dermal Irritation and Dermal Toxicity Studies
Dinesh Gangoda
 
chronic dermal and inhalational studies as per OECD
chronic dermal and inhalational studies as per OECDchronic dermal and inhalational studies as per OECD
chronic dermal and inhalational studies as per OECD
Sohil Shah
 
TEST ITEM CHARACTERIZATION IN REGULATORY TOXICOLOGY STUDIES.pptx
TEST ITEM CHARACTERIZATION IN REGULATORY TOXICOLOGY STUDIES.pptxTEST ITEM CHARACTERIZATION IN REGULATORY TOXICOLOGY STUDIES.pptx
TEST ITEM CHARACTERIZATION IN REGULATORY TOXICOLOGY STUDIES.pptx
ashharnomani
 

What's hot (20)

skin sensitisation test
 skin sensitisation test skin sensitisation test
skin sensitisation test
 
Oral toxicity
Oral toxicityOral toxicity
Oral toxicity
 
OECD Guidline on acute and chronic toxicity
OECD Guidline on acute and chronic toxicityOECD Guidline on acute and chronic toxicity
OECD Guidline on acute and chronic toxicity
 
Preclinical screening of anti ulcer drugs
Preclinical screening of anti ulcer drugsPreclinical screening of anti ulcer drugs
Preclinical screening of anti ulcer drugs
 
Female reproductive toxicity studies acoording to SECHDULE Y AND ICH S5R3
Female reproductive toxicity studies acoording to SECHDULE Y AND ICH S5R3Female reproductive toxicity studies acoording to SECHDULE Y AND ICH S5R3
Female reproductive toxicity studies acoording to SECHDULE Y AND ICH S5R3
 
Schedule Y Regulation For Animal Toxicity Studies
 Schedule  Y Regulation For Animal Toxicity Studies Schedule  Y Regulation For Animal Toxicity Studies
Schedule Y Regulation For Animal Toxicity Studies
 
Anesthesia and euthanasia of experimental animal by vivek and naveen
Anesthesia and euthanasia of experimental animal by vivek and naveenAnesthesia and euthanasia of experimental animal by vivek and naveen
Anesthesia and euthanasia of experimental animal by vivek and naveen
 
test item characterization of regulatory of toxicological studies
test item characterization of regulatory of toxicological studies test item characterization of regulatory of toxicological studies
test item characterization of regulatory of toxicological studies
 
SUB ACUTE ORAL TOXICITY
SUB ACUTE ORAL TOXICITYSUB ACUTE ORAL TOXICITY
SUB ACUTE ORAL TOXICITY
 
Toxicity Studies : Acute Eye Irritation, Dermal Irritation
Toxicity Studies : Acute Eye Irritation, Dermal IrritationToxicity Studies : Acute Eye Irritation, Dermal Irritation
Toxicity Studies : Acute Eye Irritation, Dermal Irritation
 
Skin sensitisation (OECD: 406).
Skin sensitisation (OECD: 406).Skin sensitisation (OECD: 406).
Skin sensitisation (OECD: 406).
 
OECD Guideline 420: Acute oral Toxicity - Fixed Dose Procedure
OECD Guideline 420: Acute oral Toxicity - Fixed Dose ProcedureOECD Guideline 420: Acute oral Toxicity - Fixed Dose Procedure
OECD Guideline 420: Acute oral Toxicity - Fixed Dose Procedure
 
Toxicology & Regulatory Guidelines for Conducting Toxicity Study
Toxicology & Regulatory Guidelines for Conducting Toxicity StudyToxicology & Regulatory Guidelines for Conducting Toxicity Study
Toxicology & Regulatory Guidelines for Conducting Toxicity Study
 
Cpcsea guidelines
Cpcsea guidelines Cpcsea guidelines
Cpcsea guidelines
 
TOXICOKINETICS EVALUATION IN PRECLINICAL STUDIES.pptx
TOXICOKINETICS EVALUATION IN PRECLINICAL STUDIES.pptxTOXICOKINETICS EVALUATION IN PRECLINICAL STUDIES.pptx
TOXICOKINETICS EVALUATION IN PRECLINICAL STUDIES.pptx
 
Schedule y for toxicity studies
Schedule y  for toxicity studiesSchedule y  for toxicity studies
Schedule y for toxicity studies
 
Screening Methods of Antihypertensive Agents
Screening Methods of Antihypertensive AgentsScreening Methods of Antihypertensive Agents
Screening Methods of Antihypertensive Agents
 
Dermal Irritation and Dermal Toxicity Studies
Dermal Irritation and Dermal Toxicity Studies Dermal Irritation and Dermal Toxicity Studies
Dermal Irritation and Dermal Toxicity Studies
 
chronic dermal and inhalational studies as per OECD
chronic dermal and inhalational studies as per OECDchronic dermal and inhalational studies as per OECD
chronic dermal and inhalational studies as per OECD
 
TEST ITEM CHARACTERIZATION IN REGULATORY TOXICOLOGY STUDIES.pptx
TEST ITEM CHARACTERIZATION IN REGULATORY TOXICOLOGY STUDIES.pptxTEST ITEM CHARACTERIZATION IN REGULATORY TOXICOLOGY STUDIES.pptx
TEST ITEM CHARACTERIZATION IN REGULATORY TOXICOLOGY STUDIES.pptx
 

Similar to Acute oral Toxicity Up-Down Procedure 425 guideline

AT425.pptx
AT425.pptxAT425.pptx
AT425.pptx
SOUMYA PURANAM
 
Acute toxicity studies-425
Acute toxicity studies-425Acute toxicity studies-425
Acute toxicity studies-425
jeshicabulsara
 
Acute Toxicity by OECD Guidelines
Acute Toxicity by OECD Guidelines Acute Toxicity by OECD Guidelines
Acute Toxicity by OECD Guidelines
Sagar Dalvi
 
OECD guidelines-Organisation for Economic Co-operation and Development guidel...
OECD guidelines-Organisation for Economic Co-operation and Development guidel...OECD guidelines-Organisation for Economic Co-operation and Development guidel...
OECD guidelines-Organisation for Economic Co-operation and Development guidel...
Hemadharshini Senthill
 
OECD GUIDELINES.pptx
OECD GUIDELINES.pptxOECD GUIDELINES.pptx
OECD GUIDELINES.pptx
PurushothamKN1
 
Oecd guidelines
Oecd guidelinesOecd guidelines
Oecd guidelines
Umangi Thakkar
 
OECD Guidelines
OECD GuidelinesOECD Guidelines
OECD Guidelines
Urmila Aswar
 
Reproductive toxicity studies
Reproductive toxicity studiesReproductive toxicity studies
Reproductive toxicity studies
Loveinder Bhardwaj
 
OECD Guidelines
OECD GuidelinesOECD Guidelines
OECD Guidelines
Urmila Aswar
 
Oecd guide line2
Oecd guide line2Oecd guide line2
Oecd guide line2
drkamalsahil
 
Oecd guide line2
Oecd guide line2Oecd guide line2
Oecd guide line2
drkamalsahil
 
Subacute toxicity testing as per oecd guidelines tulsi 407
Subacute toxicity testing as per oecd guidelines tulsi 407Subacute toxicity testing as per oecd guidelines tulsi 407
Subacute toxicity testing as per oecd guidelines tulsi 407
Tulsi Gulabrao Patil
 
Animal Toxicity Studies
Animal Toxicity StudiesAnimal Toxicity Studies
Animal Toxicity Studies
KartickMahaldar1
 
Acute,Sub-acute and Sub-chronic dermal toxicity studies.pptx
Acute,Sub-acute and Sub-chronic dermal toxicity studies.pptxAcute,Sub-acute and Sub-chronic dermal toxicity studies.pptx
Acute,Sub-acute and Sub-chronic dermal toxicity studies.pptx
Dublinmatcher
 
Reproductive toxicology
Reproductive toxicologyReproductive toxicology
Reproductive toxicology
Aanchal46
 
In vivo Carcinogenesity study PHARMACY.pptx
In vivo Carcinogenesity study PHARMACY.pptxIn vivo Carcinogenesity study PHARMACY.pptx
In vivo Carcinogenesity study PHARMACY.pptx
subhamsourajit1
 
General toxicology
General toxicologyGeneral toxicology
General toxicology
Asif Yahya
 
INHALATIONAL TOXICITY STUDIES.M pharmacy
INHALATIONAL TOXICITY STUDIES.M pharmacyINHALATIONAL TOXICITY STUDIES.M pharmacy
INHALATIONAL TOXICITY STUDIES.M pharmacy
AartiPal23
 
Sub acute
Sub acuteSub acute
Difference between toxicity studies
Difference between toxicity studiesDifference between toxicity studies
Difference between toxicity studies
SSR COLLEGE OF PHARMACY
 

Similar to Acute oral Toxicity Up-Down Procedure 425 guideline (20)

AT425.pptx
AT425.pptxAT425.pptx
AT425.pptx
 
Acute toxicity studies-425
Acute toxicity studies-425Acute toxicity studies-425
Acute toxicity studies-425
 
Acute Toxicity by OECD Guidelines
Acute Toxicity by OECD Guidelines Acute Toxicity by OECD Guidelines
Acute Toxicity by OECD Guidelines
 
OECD guidelines-Organisation for Economic Co-operation and Development guidel...
OECD guidelines-Organisation for Economic Co-operation and Development guidel...OECD guidelines-Organisation for Economic Co-operation and Development guidel...
OECD guidelines-Organisation for Economic Co-operation and Development guidel...
 
OECD GUIDELINES.pptx
OECD GUIDELINES.pptxOECD GUIDELINES.pptx
OECD GUIDELINES.pptx
 
Oecd guidelines
Oecd guidelinesOecd guidelines
Oecd guidelines
 
OECD Guidelines
OECD GuidelinesOECD Guidelines
OECD Guidelines
 
Reproductive toxicity studies
Reproductive toxicity studiesReproductive toxicity studies
Reproductive toxicity studies
 
OECD Guidelines
OECD GuidelinesOECD Guidelines
OECD Guidelines
 
Oecd guide line2
Oecd guide line2Oecd guide line2
Oecd guide line2
 
Oecd guide line2
Oecd guide line2Oecd guide line2
Oecd guide line2
 
Subacute toxicity testing as per oecd guidelines tulsi 407
Subacute toxicity testing as per oecd guidelines tulsi 407Subacute toxicity testing as per oecd guidelines tulsi 407
Subacute toxicity testing as per oecd guidelines tulsi 407
 
Animal Toxicity Studies
Animal Toxicity StudiesAnimal Toxicity Studies
Animal Toxicity Studies
 
Acute,Sub-acute and Sub-chronic dermal toxicity studies.pptx
Acute,Sub-acute and Sub-chronic dermal toxicity studies.pptxAcute,Sub-acute and Sub-chronic dermal toxicity studies.pptx
Acute,Sub-acute and Sub-chronic dermal toxicity studies.pptx
 
Reproductive toxicology
Reproductive toxicologyReproductive toxicology
Reproductive toxicology
 
In vivo Carcinogenesity study PHARMACY.pptx
In vivo Carcinogenesity study PHARMACY.pptxIn vivo Carcinogenesity study PHARMACY.pptx
In vivo Carcinogenesity study PHARMACY.pptx
 
General toxicology
General toxicologyGeneral toxicology
General toxicology
 
INHALATIONAL TOXICITY STUDIES.M pharmacy
INHALATIONAL TOXICITY STUDIES.M pharmacyINHALATIONAL TOXICITY STUDIES.M pharmacy
INHALATIONAL TOXICITY STUDIES.M pharmacy
 
Sub acute
Sub acuteSub acute
Sub acute
 
Difference between toxicity studies
Difference between toxicity studiesDifference between toxicity studies
Difference between toxicity studies
 

More from DikuNath

CLINICAL TRIAL.pptx
CLINICAL TRIAL.pptxCLINICAL TRIAL.pptx
CLINICAL TRIAL.pptx
DikuNath
 
Combinatorial Chemistry presentation by dixhu raj dixit.pptx
Combinatorial Chemistry presentation by dixhu raj dixit.pptxCombinatorial Chemistry presentation by dixhu raj dixit.pptx
Combinatorial Chemistry presentation by dixhu raj dixit.pptx
DikuNath
 
Neurohemoral transmission Autonomic nervous System.pptx
Neurohemoral transmission Autonomic nervous System.pptxNeurohemoral transmission Autonomic nervous System.pptx
Neurohemoral transmission Autonomic nervous System.pptx
DikuNath
 
Mycology and parasitology
Mycology and parasitologyMycology and parasitology
Mycology and parasitology
DikuNath
 
presentation topic on ligand gated ion channel receptor by dixhu raj Dixit.pptx
presentation topic on ligand gated ion channel receptor by dixhu raj Dixit.pptxpresentation topic on ligand gated ion channel receptor by dixhu raj Dixit.pptx
presentation topic on ligand gated ion channel receptor by dixhu raj Dixit.pptx
DikuNath
 
presentation Route of drug Administration by dixhu raj Dixit.pptx
presentation Route of drug Administration by dixhu raj Dixit.pptxpresentation Route of drug Administration by dixhu raj Dixit.pptx
presentation Route of drug Administration by dixhu raj Dixit.pptx
DikuNath
 

More from DikuNath (6)

CLINICAL TRIAL.pptx
CLINICAL TRIAL.pptxCLINICAL TRIAL.pptx
CLINICAL TRIAL.pptx
 
Combinatorial Chemistry presentation by dixhu raj dixit.pptx
Combinatorial Chemistry presentation by dixhu raj dixit.pptxCombinatorial Chemistry presentation by dixhu raj dixit.pptx
Combinatorial Chemistry presentation by dixhu raj dixit.pptx
 
Neurohemoral transmission Autonomic nervous System.pptx
Neurohemoral transmission Autonomic nervous System.pptxNeurohemoral transmission Autonomic nervous System.pptx
Neurohemoral transmission Autonomic nervous System.pptx
 
Mycology and parasitology
Mycology and parasitologyMycology and parasitology
Mycology and parasitology
 
presentation topic on ligand gated ion channel receptor by dixhu raj Dixit.pptx
presentation topic on ligand gated ion channel receptor by dixhu raj Dixit.pptxpresentation topic on ligand gated ion channel receptor by dixhu raj Dixit.pptx
presentation topic on ligand gated ion channel receptor by dixhu raj Dixit.pptx
 
presentation Route of drug Administration by dixhu raj Dixit.pptx
presentation Route of drug Administration by dixhu raj Dixit.pptxpresentation Route of drug Administration by dixhu raj Dixit.pptx
presentation Route of drug Administration by dixhu raj Dixit.pptx
 

Recently uploaded

CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
rishi2789
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
HongBiThi1
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
19various
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
walterHu5
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
shivalingatalekar1
 
The Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in IndiaThe Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in India
Swastik Ayurveda
 
Top Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in IndiaTop Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in India
SwisschemDerma
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
chiranthgowda16
 
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
rightmanforbloodline
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
LaniyaNasrink
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
Swastik Ayurveda
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
suvadeepdas911
 
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
rightmanforbloodline
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
bkling
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
Josep Vidal-Alaball
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
Diabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatmentDiabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatment
arahmanzai5
 

Recently uploaded (20)

CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
 
The Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in IndiaThe Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in India
 
Top Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in IndiaTop Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in India
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
 
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
 
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
Diabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatmentDiabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatment
 

Acute oral Toxicity Up-Down Procedure 425 guideline

  • 1. ACUTE ORAL TOXICITY- UP DOWN PROCEDURE (425 GUIDELINE) NAME-DIXHU RAJ DIXIT CLASS-M.PHARM PHARMACOLOGY 2ND SEM ROLLNO-007
  • 2. INTRODUCTION • OECD guideline for the testing of chemicals are periodically reviewed in the light of scientific progress or changing. • The concept of the up-down testing approach was first described by Dixon and Mood. • In 1985 Bruce proposed to use an up and down procedure for the determination of acute toxicity of chemicals • The study comparing result obtained with the UDP the conventional LD50 test and fixed dose procedure was published in 1995. • The test procedure described in the guideline is of value in minimizing the numbering of animals required to estimate the acute oral toxicity of chemicals • Guidance on the selection of the most appropriate test method for a given purpose can be found in the in the guidance document on oral toxicity testing.
  • 3. INITIAL CONSIDERATION • The testing laboratory should be consider all available information on the test substance prior to conducting the study. • Identity and chemical structure of the test substance its physical chemical properties the result of any other in vitro and in vivo toxicity test on the substance . • Toxicological data on structurally related substances or similar mixtures and the anticipated use of the substance. • The method permits estimation of an LD50 with a confidence interval and results allow a substance to be ranked and classified according to globally harmonised system for the classification of chemicals which cause acute toxicity.
  • 4. • Dose starting near 175 mg/kg and using half log unit (dose progression by factor 3.2) between doses will procedure best results. • Test substance, at doses that are known to cause marked pain and distress due to corrosive or severely irritant actions, need not be administered. • The method would not be practical to use when considerly delayed death ( five days Or more) can be expected.
  • 5. PRINCIPLE OF LIMIT TEST • The limit is a sequential test that is uses a maximum of 5 animals. A test dose of 2000, or expectationally 5000mg/kg , may be used. • The selection of sequential test plan increases the statistical power and also has been made to intentionally bias the procedure towards rejection of the limit test for compound with LD50 near the limit dose.
  • 6. PRINCIPLE OF MAIN TEST • The main test consist of a single ordered dose progression in which animals are dosed, on at a time, at a minimum of 48 hour interval. • The first animal Receives a dose a step below the level of the best estimate of the LD50. • If the animal Survive the dose for the next animal is incresed by factor 3.2 times the original dose; if it dies, the dose for the next animal is decreased by a similar dose progression. • Each animal should be observed carefully for up to 48 hours before making a decision on whether and how much to dose the next animal. • The decission is based on the 48 hour survival pattern of all animals up to that time. • The LD50 is calculated using the method of maximum likelihood.
  • 7. DESCRIPTION OF THE METHOD • SELECTION OF ANIMAL SPECIES— The preferred rodent species is the rat, normally female rat are used. • When toxicological and toxicokinetic properties of structurally related chemicals are studied, male are likely to be more sensitive. • Criteria for femals rats---- • They should be nulliparous and non pregnant. • Should be between 8 to 12 years old. • Weight +-20% of initial mean weight.
  • 8. HOUSING AND FREEDING CONDITIONS- 1.Temperature in the experimental animal room should be 22°c . 2.Humidity should be 30-60% not exceeding 70%. 3.Lightening should be artificial, the sequence being 12 hours light and 12 hours dark. 4.The animal House are individually. 5.For feeding, conventional rodent laboratory diets may be used with in unlimited supply of drinking water.
  • 9. • PREPARATION OF ANIMAL- • The animal are randomly selected, marked to permit individual identification, and kept in. Their cages for at least 5 days prior to dosing to allow for acclimatization to laboratory conditions. • Ensure that animals are available in the appropriate size and age range for the entire study. • PREPARATION OF DOSES- • Test Substances should be administerd in a consent volume by varying the concentration of the dosing preparation. • In rodents, the volume should not normally exceed 1ml/100 g of body weight ; however in the case of aqueous solutions, 2ml/100 g body weight can be considered. • For vehicle other than water, the toxicological charecterstics of the vehicle should be known.
  • 10. PROCEDURE • ADMINISTRATION OF DOSES- • The test substance is administered in a single dose by gavage using a stomach tube or suitable intubation cannula. • Animals should be fasted prior to dosing( ex-rat, food but not water should be witheld overnight ; with the mouse, food but not water should be witheld for 3-4 hours) • Animal should be weighed and the test substance administered and the dose is calculated according to the body weight. • After the substance has been administered, food may be witheld for a further 3-4 hours in rats or 1-2 hours in mice.
  • 11. LIMIT TEST AND MAIN TEST • The limit test is primarily used in Situation where the experimenter has information indicating that the test material is likely to be nontoxic, I.e.having toxicity below regulatory limit doses. • There is little or no information about it’s toxicity, or in which the test material is expected to be toxic, the main test should be performed. • Information about the toxicity of the test material can be gained from knowledge about similar tested compounds or similar tested mixtures or products, taking into consideration the identity and percentage of components.
  • 12. LIMIT TEST • Dose one animal at the test dose. • If the animal dies, conduct the main test to determine the LD50. • If the animal survives, does four additional animals sequentially so that a total of five animals are tested. If three animals die, the limit test is terminated and the main test is performed. • If an animal unexpectedly dies late in the study, and there are other survivors it is appreciate to stop dosing and observe all animals to see if other animals will also die during a similar observation period. • The result are evaluated as follows (O= survival, X-Death) • The LD50 is less than the test dose(2000mg/kg) when three or more animal die. • O XO XX • O OX XX • O XX OX • O XX X • If a third animal dies, conduct the main test.
  • 13. LIMIT TEST AT 5000 MG/KG • Dose one animal at the test dose. • If the animal dies, conduct the main test to determine LD50. • If the Animal survives, dose two additional animals. If both animals survive, the LD50 is greater than the limit dose and the test is terminated. • The LD 50 Is less than the test dose( 5000mg/kg) when three or more animal die. • The LD 50 is greater than the test done (5000mg/kg) when three or more animals survive.
  • 14. MAIN TEST • Single animal are dosed in sequence usually at 48 hour intervals • For selecting starting dose, information on structurally related substances and results of any other toxicity tests on the test material, should be used to approximate the LD50 as well as the slope of these dose response curve. • The dose procession factor should remain constant throughout testing • When there is no Information on the slope of the substance to be tested, a dose progression factor of 3.2 is used. • Using default progression factor, doses would be selected from the sequence 1.75,5.5,17.5,55,175,550,2000.
  • 15. • The testing criteria stops when one of the following stoping criteria first is met------ • 3 consecutive animals survive at thr upper bound • 5 reversals occur in any 6 consecutive animal tested. • At least 4 animals have followed the first reversal and the specified likelihood –ratios exceed . If an animal unexpectedly dies late in the study and there are other survivors at that dose or above, it is appropriate to stop dosing and observe all animals to see if other animals will also die during a similar observation period. If subsequent survivors also die, and it appears that all dose levels exceed the LD50 it would be most appropriate to start the study again beginning at least two steps below the lowest dose with deaths (and increasing the observation period) since the technique is most accurate when the starting dose is below the LD50. If subsequent animals survive at or above the dose of the animal that dies, it is not necessary to change the dose progression
  • 16. OBSERVATION • Animals are observed individually at least once during the first 30 minutes after dosing, periodically during the first 24 hours (with special attention given during the first 4 hours), and daily thereafter, for a total of 14 days, except where they need to be removed from the study and humanely killed for animal welfare reasons or are found dead. • Observations should include changes in skin and fur, eyes and mucous membranes, and also respiratory, circulatory, autonomic and central nervous systems, and somatomotor activity and behaviour pattern. Attention should be directed to observations of tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma.
  • 17. BODY WEIGHT AND PATHOLOGY Body weight- Individual weights of animals should be determined shortly before the test substance is administered and at least weekly thereafter. Weight changes should be calculated and recorded. At the end of the test surviving animals are weighed and then humanely killed. Pathology- All animals (including those which die during the test or are removed from the study for animal welfare reasons) should be subjected to gross necropsy. All gross pathological changes should be recorded for each animal.
  • 18. DATA AND REPORTING Individual animal data should be provided. Additionally, all data should be summarised in tabular form, showing for each test dose the number of animals used, the number of animals displaying signs of toxicity (the number of animals found dead during the test or killed for humane reasons, time of death of individual animals, a description and the time course of toxic effects and reversibility, and necropsy finding
  • 19. TEST REPORT AND RESULT • he test report must include the following information: • • Test substance: • − physical nature, purity and, where relevant, physical-chemical properties (including isomerisation); • − identification data, including CAS number. • • Vehicle (if appropriate): • • − justification for choice of vehicle, if other than water. •